Bristol-Myers Squibb

Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018

Cabometyx has emerged as a key growth driver for Exelixis in 2017.<p>The company is aggressively exploring cabozantinib as monotherapy or in combination …

Stocks

Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?

Shares have risen by 75% since bringing this stock to the attention of readers three weeks ago.<p>Below I provide a very brief recap of the bullish …

Stocks

Medtronic's Strong Q1 Helps Send Healthcare Stocks Higher

Healthcare stocks are helping markets power forward on Tuesday.<p>The Health Care SPDR ETF (XLV) was rising nearly 1% in afternoon trading, boosted in …

Stocks

Innate Pharma provides an update on Lirilumab

<b>INNATE PHARMA PROVIDES AN UPDATE ON LIRILUMAB</b>

Cancer

Portola Pharmaceuticals (Part II): Will Shareholder Activism Unlock Further Value?

Juggernaut Capital recently disclosed shares in Portola.<p>The voice of this powerhouse hedge fund can guide the management on the right path.<p>The …

Stocks

Flagship-backed cancer biotech Ensemble quietly shuts down

During its 13-year existence, the Cambridge biotech made waves by announcing a series of partnership deals with large drugmakers. But it raised …

Boston

Success through Collaboration

If there’s one industry that stands out as a bastion of secrecy and cutthroat competition, it’s pharmaceuticals. So what in the world were …

Innovation

Roche shares lifted by positive drug trials

and<p>Shares in Roche rose almost 7 per cent on Monday after the Swiss pharmaceuticals group was buoyed by strong results from two drug trials including …

Cancer

Roche's prospects look sunnier, thanks to blockbuster-boosting data for Hemlibra, Tecentriq

Two of Roche's new generation of drugs—including the just-approved hemophilia therapy Hemlibra—racked up new data Monday that bolster their case for …

Cancer

Roche: The Big Pipeline Payoff

It isn’t every day that a major drug maker unveils a big clinical trial win. But two on the same day?<p>Roche Holding (RHHBY) shares were on the rise …

Pharma

Six promising stocks to buy when the biotech correction ends - MarketWatch

Some investors are waiting for a decline in the U.S. stock market to put new money to work.<p>They just got one — in biotech.<p>As of Nov. 14, biotech …

Stocks

Roche Cancer Drug Rises To Challenge Merck, Bristol-Myers

Tecentriq, a cancer immunotherapy developed by the Swiss drug giant Roche, slowed the progression of previously untreated lung cancer in a large clinical trial when combined with a chemotherapy regimen, the drug giant said.<p>“We are extremely encouraged by these results and will submit these data to …

Cancer

Asian shares advance as Wall Street regains ground

TOKYO — Asian shares edged mostly higher Tuesday after Wall Street regained lost ground overnight amid subdued trading ahead of the Thanksgiving …

Markets

Brainstorm Health: Chinese Health Startups, Roche Stock Spikes, Americans Don't Eat Veggies

Good morning. The nations of the world now spend nearly $8 trillion on healthcare, according to a report in The Lancet. By 2040, say data scientists …

Energy

3 Biotech Stocks to Be Thankful for This Year

If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.<p>Anyone who …

Stocks

Pfizer Scores Sutent Win, But Bristol-Myers Looks To Steal Its Thunder

Pfizer wins expanded access for Sutent to stop patients from recurring in cancer after having their kidney removed.<p>The newly expanded indication will …

Business

10 Frightening Lung-Cancer Statistics and 3 Top Companies Looking to Do Something About It

Cancer immunotherapies and targeted therapies offer renewed hope to lung-cancer patients.<p>There's arguably no scarier six-letter word than "cancer." …

Cancer

3 Biotech Stocks That Soared: Are They Buys?

Could Nektar Therapeutics, Wave Life Sciences, and Savara go even higher after huge gains this past week?<p>Some of the biggest moves week in and week …

Stocks

Albireo Pharma: Updates To Thesis

Shares have risen nearly 20% since my initial write-up and I believe the initial bull thesis remains intact.<p>In late October the company reported …

Business

Here's Why Nektar Therapeutics Is Skyrocketing 70% in November

After the company told investors that it plans to file for Food and Drug Administration approval for a drug that could disrupt the $12 billion market for opioid painkillers, <b>Nektar Therapeutics</b> (NASDAQ: NKTR) shares shot higher. However, that wasn't the only good news it's released so far this …

Stocks

Trump Rails Against Drug Industry, but Turns to its Ranks to Fill Administration

WASHINGTON—President Trump has vilified the pharmaceutical industry and made bold promises to lower prescription drug prices. But when it comes to …

Pharma

Can This Tiny Biotech Stock Pay Off Big for Celgene?

Data from a small-cap biotech stock that's working with Celgene on a new approach to cancer treatment is expected in 2018.<p><b>Celgene Corp</b> (NASDAQ:CELG) …

Stocks

biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score | European Heart Journal

Aims<p>In atrial fibrillation (AF), mortality remains high despite effective anticoagulation. A model predicting the risk of death in these patients is …

PubMed

Pancreatic cancer is often deadly, but new discoveries are raising hope

In the Lab<p>Pancreatic cancer is often deadly. But recent discoveries are starting to unravel its mysteries — and raise hope<p>P<p>ancreatic cancer is …

Cancer

Maker of Aerosoles shoes to lay off 141 N.J. workers amid store closings

The Edison-based women's shoemaker earlier filed for bankruptcyEDISON -- Two months after announcing store closures and filing for bankruptcy, New …

New Jersey

Harry Boxer on four stocks rallying today - MarketWatch

Stocks with strong earnings results and other positive news continue to top our list of charts to watch today.<p><b>Collegium Pharmaceutical Inc.</b> COLL, …

Business

AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth

Ovarian cancer treatment has changed dramatically, and with several new drugs now duking it out in that market, the battle for share is changing, …

Cancer

3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock

What's the best big pharma stock?<p>Of course, "best" can mean different things to different people. But with stocks, there are key metrics that can be used to determine which are better than others. And if one stock clearly dominates in several of those metrics, it has a strong argument in being …

Stocks

Biotech firms race to recruit good bugs in war on cancer

(Reuters) - Biotech companies are competing to develop medicines using “bugs as drugs” to fight cancer, building on the latest scientific findings that patients with high levels of good gut bacteria are more likely to respond to modern immunotherapy.<p>A cancer cell (white) being attacked by two …

Cancer

Which Will Pfizer Buy? Biogen or Bristol-Myers Squibb

Everyone has heard the talk. <b>Pfizer</b> (PFE) is getting ready to make a deal. the skinny on Wall Street is that the U.S. pharmaceutical giant has its …

Alzheimer's Disease